Glioblastoma is the most common and aggressive brain tumor in adults. Despite surgery, radiation, and chemotherapy, survival rates remain low, which emphasizes the urgent need for improved therapies. Current preclinical models use untreated tumors, which do not reflect the clinical scenario where patients already receive initial treatments. This review examines the effects of current treatments on the properties of recurrent tumors and evaluates preclinical models that incorporate these standard treatments to better mimic real patient conditions. Improving these models could help to identify more effective treatments, potentially leading to better outcomes for glioblastoma patients.
Pannita achieves a perfect Bradford assay
Congratulations to Pannita on a perfect Bradford protein assay! This is a rare accomplishment, with only a few BHL members having achieved it over the years. Following a long-standing lab tradition, we celebrated Pannita’s perfect Bradford with a pizza party.
October 19, 2026
